Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roger Haddad

Anesthesiology Detroit, MI Doctor of Osteopathy

NPI 1366767469 CMS profile 333854

2799 W Grand Blvd, Detroit, MI 48202

Open in the dashboard

General payments

$13,208

177 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roger Haddad of Detroit, MI is reported in the CMS Open Payments database as having received $13,208 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,270 19
2024 General $3,177 53
2023 General $2,723 34
2022 General $3,393 32
2021 General $533 8
2020 General $546 11
2019 General $1,567 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roger Haddad
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Roger Haddad were reported at $1,270. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Roger Haddad Anesthesiology median Middle half National median
2019 $1,567 $72 $23–$151 $163
2020 $546 $36 $17–$120 $114
2021 $533 $49 $21–$135 $132
2022 $3,393 $52 $22–$144 $149
2023 $2,723 $53 $23–$143 $160
2024 $3,177 $55 $25–$150 $164
2025 $1,270 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $5,421 91 payments
  2. Abbott Laboratories $1,470 14 payments
  3. Boston Scientific Corporation $1,215 15 payments
  4. Pacira Pharmaceuticals Incorporated $1,203 4 payments
  5. Globus Medical, Inc. $813 12 payments
  6. Vertos Medical, Inc. $759 9 payments
  7. Medtronic, Inc. $505 9 payments
  8. Avanos Medical $281 5 payments
  9. Nalu Medical, Inc. $260 3 payments
  10. Medtronic USA, Inc. $251 2 payments
  11. Other $1,029 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,537 168 payments
  2. Travel and Lodging $1,248 7 payments
  3. Honoraria $400 1 payment
  4. Education $23 1 payment
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulator $2,276 46 payments
  2. Omnia $1,555 18 payments
  3. Senza Spinal Cord Stimulation System $1,411 25 payments
  4. PROCLAIM $1,035 9 payments
  5. WaveWriter Alpha Prime 16 $969 13 payments
  6. Zilretta $803 3 payments
  7. Iovera $803 3 payments
  8. Senza Spinal Cord Stimulator $791 11 payments
  9. mild Device Kit $759 9 payments
  10. INTELLIS ADAPTIVESTIM $461 6 payments
  11. Other $3,424 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

204

Median for Anesthesiology: 322

Drug cost

$2,258

Median for Anesthesiology: $8,738

Branded share of claims

30.4%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 61 $891
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 40 $424
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $328
Tizanidine Hcl Generic 12 $168
Duloxetine Hcl Generic 11 $138
Methocarbamol Generic 21 $136
Pregabalin Generic 13 $117
Tramadol Hcl Generic 13 $36
Meloxicam Generic 11 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$69,095

Medicare's payments for the services billed

Medicare patients

339

Average age 71

Services billed

933

219 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Depression 34%
Ischemic heart disease 32%
Chronic kidney disease 28%
COPD 22%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $126
$126 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record